Cuts FY24 revenue view to (4.5%) to (3.5%) from (2%) to flat, consensus $4.79B.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem reports Q3 EPS (60c), consensus (74c)
- Verastem completes rolling NDA submission to FDA for Avutometinib+Defactinib
- VSTM Earnings this Week: How Will it Perform?
- Truist remains bullish on Verastem, says weakness in shares ‘an overreaction’
- Verastem Advances Cancer Treatment with Promising Trial Results